You are here: Industry Insights > eye drug

News List

Takeda recalls eye drug Natpara but warns patients not to abruptly stop treatment fiercepharma
September 08, 2019
Takeda Pharmaceutical’s been looking for a buyer for Natpara to provide some debt relief, but it has just run into some complicating circumstances. It is having to recall the eye drug from the market, a move it says may be very challenging for patients.
Horizon bulks up sales force ahead of $750M inflammatory eye drug launch fiercepharma
June 28, 2019
Horizon Therapeutics—until recently known as Horizon Pharma—is headed for an FDA filing for its inflammatory eye drug teprotumumab. To prepare for the potential launch, the company has set out to expand its sales team.
Horizon bulks up sales force ahead of $750M inflammatory eye drug launch fiercepharma
June 28, 2019
Horizon Therapeutics—until recently known as Horizon Pharma—is headed for an FDA filing for its inflammatory eye drug teprotumumab. To prepare for the potential launch, the company has set out to expand its sales team.
Novartis’ eye drug on par with Eylea but with fewer injections pharmatimes
June 23, 2017
Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.
Novartis next generation eye drug outperforms Eylea pharmaphorum
June 22, 2017
Novartis is to file its next-generation eye drug in 2018 after it won out in a head-to-head trial with Bayer/Regeneron’s rival, Eylea.